Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Therapeutic potential of menstrual blood-derived endometrial stem cells in cardiac diseases.

Liu Y., Niu R., Li W., Lin J., Stamm C., Steinhoff G.

Clinical Trial on Cardiovascular Disease, Immune Modulation, published in Cell Mol Life Sci (2019) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Cell Mol Life Sci (2019)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
30721319
PMCID
PMC11105669
DOI
10.1007/s00018-019-03019-2
Citations
50

Abstract (original English)

Despite significant developments in medical and surgical strategies, cardiac diseases remain the leading causes of morbidity and mortality worldwide. Numerous studies involving preclinical and clinical trials have confirmed that stem cell transplantation can help improve cardiac function and regenerate damaged cardiac tissue, and stem cells isolated from bone marrow, heart tissue, adipose tissue and umbilical cord are the primary candidates for transplantation. During the past decade, menstrual blood-derived endometrial stem cells (MenSCs) have gradually become a promising alternative for stem cell-based therapy due to their comprehensive advantages, which include their ability to be periodically and non-invasively collected, their abundant source material, their ability to be regularly donated, their superior proliferative capacity and their ability to be used for autologous transplantation. MenSCs have shown positive therapeutic potential for the treatment of various diseases. Therefore, aside from a brief introduction of the biological characteristics of MenSCs, this review focuses on the progress being made in evaluating the functional improvement of damaged cardiac tissue after MenSC transplantation through preclinical and clinical studies. Based on published reports, we conclude that the paracrine effect, transdifferentiation and immunomodulation by MenSC promote both reg

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdultAgedCardiac RehabilitationCardiovascular DiseasesCell TransdifferentiationCell- and Tissue-Based TherapyEndometriumFemaleHumansMenstruation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research